NASDAQ:ATRIAtrion Competitors & Alternatives

Atrion (NASDAQ:ATRI) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Atrion and Align Technology, as provided by MarketBeat.com.

Align Technology has a consensus target price of $254.8182, indicating a potential downside of 6.76%. Given Align Technology's higher possible upside, analysts plainly believe Align Technology is more favorable than Atrion.

Volatility & Risk

Atrion has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Profitability

This table compares Atrion and Align Technology's net margins, return on equity and return on assets.

Insider and Institutional Ownership

65.8% of Atrion shares are held by institutional investors. Comparatively, 86.0% of Align Technology shares are held by institutional investors. 22.4% of Atrion shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atrion and Align Technology's top-line revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Atrion.

Summary

Align Technology beats Atrion on 10 of the 12 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Valuation & Earnings

This table compares Atrion and West Pharmaceutical Services' top-line revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than Atrion.

Dividends

Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. West Pharmaceutical Services pays an annual dividend of $0.64 per share and has a dividend yield of 0.3%. West Pharmaceutical Services pays out 19.8% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and West Pharmaceutical Services has increased its dividend for 27 consecutive years.

Profitability

This table compares Atrion and West Pharmaceutical Services' net margins, return on equity and return on assets.

Insider and Institutional Ownership

65.8% of Atrion shares are owned by institutional investors. Comparatively, 90.6% of West Pharmaceutical Services shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Atrion has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Atrion and West Pharmaceutical Services, as provided by MarketBeat.com.

West Pharmaceutical Services has a consensus target price of $200.00, suggesting a potential downside of 13.88%. Given West Pharmaceutical Services' higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Atrion.

Summary

West Pharmaceutical Services beats Atrion on 9 of the 14 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and Cooper Companies (NYSE:COO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Earnings & Valuation

This table compares Atrion and Cooper Companies' revenue, earnings per share (EPS) and valuation.

Cooper Companies has higher revenue and earnings than Atrion.

Dividends

Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. Cooper Companies pays out 0.5% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Atrion and Cooper Companies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Atrion and Cooper Companies, as reported by MarketBeat.

Cooper Companies has a consensus price target of $330.7273, suggesting a potential upside of 14.28%. Given Cooper Companies' higher possible upside, analysts plainly believe Cooper Companies is more favorable than Atrion.

Institutional & Insider Ownership

65.8% of Atrion shares are owned by institutional investors. Comparatively, 88.1% of Cooper Companies shares are owned by institutional investors. 22.4% of Atrion shares are owned by insiders. Comparatively, 1.4% of Cooper Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Atrion has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Cooper Companies has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Summary

Atrion beats Cooper Companies on 8 of the 15 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

87.0% of Quidel shares are held by institutional investors. Comparatively, 65.8% of Atrion shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 22.4% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Quidel and Atrion's gross revenue, earnings per share (EPS) and valuation.

Quidel has higher revenue and earnings than Atrion.

Profitability

This table compares Quidel and Atrion's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Quidel and Atrion, as provided by MarketBeat.com.

Quidel currently has a consensus target price of $161.8333, indicating a potential downside of 34.38%. Given Quidel's higher possible upside, equities research analysts clearly believe Quidel is more favorable than Atrion.

Volatility & Risk

Quidel has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

Quidel beats Atrion on 10 of the 12 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Analyst Recommendations

This is a summary of recent ratings and price targets for DENTSPLY SIRONA and Atrion, as provided by MarketBeat.

DENTSPLY SIRONA currently has a consensus price target of $49.1538, indicating a potential upside of 17.09%. Given DENTSPLY SIRONA's higher probable upside, research analysts clearly believe DENTSPLY SIRONA is more favorable than Atrion.

Valuation and Earnings

This table compares DENTSPLY SIRONA and Atrion's top-line revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Atrion.

Institutional and Insider Ownership

95.4% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 65.8% of Atrion shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 22.4% of Atrion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 1.0%. Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. DENTSPLY SIRONA has raised its dividend for 8 consecutive years and Atrion has raised its dividend for 17 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares DENTSPLY SIRONA and Atrion's net margins, return on equity and return on assets.

Risk and Volatility

DENTSPLY SIRONA has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.

Summary

Atrion beats DENTSPLY SIRONA on 8 of the 15 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

99.2% of Haemonetics shares are owned by institutional investors. Comparatively, 65.8% of Atrion shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 22.4% of Atrion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Haemonetics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Earnings and Valuation

This table compares Haemonetics and Atrion's top-line revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than Atrion.

Profitability

This table compares Haemonetics and Atrion's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Haemonetics and Atrion, as provided by MarketBeat.

Haemonetics currently has a consensus price target of $130.1667, indicating a potential upside of 49.45%. Given Haemonetics' higher probable upside, analysts clearly believe Haemonetics is more favorable than Atrion.

Summary

Haemonetics beats Atrion on 8 of the 12 factors compared between the two stocks.